GP antibiotic prescribing drops further but drug resistance still rising

antimicrobial resistance

GPs have further reduced antibiotic prescribing, but ongoing rising antimicrobial resistance means more work is needed, the UK Health Security Agency (UKHSA) has concluded.

National surveillance data shows a 10.7% fall in antibiotic prescribing between 2019 and 2025 from 17.8 to 15.9 defined daily doses per 1,000 inhabitants per day.

Figures also show that antibiotic prescribing in children aged up to nine years old fell from 32% to 28%, close to the goal of 27 with almost half of ICBs hitting the target.

But the total number of antibiotic-resistant infections continued to rise in 2025, with an average of 406 reported cases each week, the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report found.

Overall, a total of 21,129 antibiotic-resistant bacteraemia cases were reported in 2025, up 16.8% from 18,086 in 2019.

While the pace of the increase appears to be slowing, there are now more episodes of antibiotic-resistant bacteraemia in England than at any other time on record, UKHSA said.

The issue is also impacting those in the most deprived areas who also have a higher burden of infection overall and have higher rates of antibiotic prescribing, the report noted.

There was a 44.2% higher rate of resistant bacteraemia in the most deprived group compared to the least deprived and the gap between the rate among the most and least deprived group has increased since 2019 when it was 29% higher, the report found.

The data suggests a target set in the UK government’s 5-year action plan for antimicrobial resistance 2024 to 2029 for resistant infections in 2029 to be at the same level as 2019, may be missed.

In England, a 25.7% increase in a selected set of antibiotic-resistant infections has been seen since 2019.

It shows there is ‘work to do in terms of using antibiotics and other antimicrobial medicines more responsibly’, the report said.

The National Action Plan also sets a target to reduce the overall use of antimicrobial medicines in people by 5% by 2029 compared with 2019 levels.

Total antibiotic use in England last year fell compared with 2024, ‘indicating early progress’ towards the target, it added.

Most antibiotics in England are prescribed in GP settings, accounting for 65.4% of all prescriptions in 2025. Prescribing fell in all sectors except hospital where it increased 5%.

But there was wide variation across the country with highest prescribing rates in the North East and lowest in the South East, due to multiple factors, including age and access to healthcare.

The report did also note that use of methenamine hippurate for urinary tract infections had increased substantially across England, particularly in primary care, while the prescribing of nitrofurantoin has gradually declined.

The decrease was most noticeable in areas where methenamine use increased the most, the report said.

More people who were given amoxicillin received a shorter, five-day course (from 69% to 74% in March 2026 compared with March 2025) and there were also 26,118 fewer amoxicillin prescriptions, UKHSA said.

Surveillance figures also showed that Pharmacy First saw over 3 million consultations in 2025/26, an increase of 42% from the previous year but there were also 1- 5% percent fewer antibiotics supplied across the seven infection pathways.

Dr Shona Arora, interim chief medical advisor at UKHSA, said: ‘Every week hundreds of people face a new reality of what it means to get an antibiotic-resistant infection, which can increase the risk of serious illness, and even death.

‘Our most deprived communities and older generations continue to be hit hardest by the effects of antimicrobial resistance, although anyone can be impacted.’

She added: ‘It is positive to see signs that ongoing efforts to promote responsible antibiotic use are having an impact but there are still significant challenges as resistant infections continue to increase.

‘We can’t rely on reducing antibiotic use alone. We need to continue our work with partners globally to prevent infections from occurring in the first place, alongside exploring new treatment options.’